A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: listed (1000), planned (749), programmed (544)

InP-BEAM

Description
Chemotherapy Protocol LYMPHOMA CARMUSTINE-CYTARABINE-ETOPOSIDE (split)-MELPHALAN (BEAM) Inpatient Regimen Regimen Lymphoma – InP-BEAM (split)-Carmustine-Cytarabine-Etoposide-Melphalan Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-BEAM.pdf

BEACOPP escalated

Description
Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONEPROCARBAZINE-VINCRISTINE (BEACOPP Escalated) Regimen • Lymphoma – BEACOPP Escalated -Bleomycin-Cyclophosphamide-DoxorubicinEtoposide-Prednisolone-Procarbazine-Vincristine
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPP-escalated.pdf

BEACOPP 14

Description
Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONEPROCARBAZINE-VINCRISTINE (BEACOPP-14) Regimen • Lymphoma – BEACOPP-14-Bleomycin-Cyclophosphamide-Doxorubicin-EtoposidePrednisolone-Procarbazine-Vincristine
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPP-14.pdf

BEACOPDac escalated

Description
Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DACARBAZINE-DOXORUBICIN-ETOPOSIDEPREDNISOLONE-VINCRISTINE (BEACOPDac Escalated) Regimen • Lymphoma – BEACOPDac Escalated-Bleomycin-Cyclophosphamide-DacarbazineDoxorubicin-Etoposide-Prednisolone-Vincristine
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPDac-escalated.pdf

Pembrolizumab_400mg skin

Description
Chemotherapy Protocol SKIN CANCER Pembrolizumab (400mg) Regimen • Skin – Pembrolizumab (400mg) Indication • Pembrolizumab is recommended; -
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Pembrolizumab-400mg.pdf

Pembrolizumab_200mg skin

Description
Regimen Chemotherapy Protocol SKIN CANCER Pembrolizumab (200mg) • Skin – Pembrolizumab (200mg) Indication • Pembrolizumab is recommended; -
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Pembrolizumab-200mg.pdf

Pembrolizumab Ver 1 skin

Description
Chemotherapy Protocol SKIN CANCER Pembrolizumab Pembrolizumab is currently available on a compassionate use basis only – not yet licensed in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinPembrolizumabVer1.pdf

Nivolumab Ver 1.1 skin

Description
Chemotherapy Protocol SKIN CANCER Nivolumab This regimen may require funding. Regimen Skin – Nivolumab Indication The treatment of advanced
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/NivolumabVer1.1.pdf

Pembrolizumab (200mg)

Description
Regimen Chemotherapy Protocol HEAD AND NECK CANCER Pembrolizumab (200mg) • Head and Neck – Pembrolizumab (200mg) Indication • Pembrolizumab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Pembrolizumab-200mg.pdf

Nivolumab_240mg

Description
Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab (240mg-14 days) Regimen • Head and Neck – Nivolumab (240mg-14 days) Indication • The tr
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab-240mg.pdf
201 to 210 of 450
Previous … 19 20 21 22 23 … Next